EpiSwitch® research and medical analysis services focus on the discovery, evaluation, validation, and monitoring of a novel class of epigenetic biomarkers known as chromosome conformation signatures ("CCSs") for use in medical testing kits, disease prediction, diagnosis, and treatment. CCSs can provide a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities

EpiSwitch® medical analysis services utilize a proprietary validated industrial platform for CCS based biomarkers.

EpiSwitch® medical analysis services utilize a proprietary validated industrial platform for CCS based biomarkers.

Chromosomal Conformation Capture

The packaging of chromosomal DNA plays a critical role in the epigenetic regulation of the whole genome. It ensures effective storage, access to genetic information and its regulation by the complex protein machinery utilised in gene expression. Known also as ‘gene loops’, ‘long-range chromosomal interactions’ and ‘chromatin domains’, CCSs have been recognised as an essential high-level framework of epigenetic regulation imposed across the whole genome and reflecting its fractal nature of organisation.

Click image to enlarge

Episwitch® Pipeline


Episwitch® Design

Proprietary pattern recognition bioinformatic algorithms used to detect specific DNA sites as high probability targets for CCS detection


Episwitch® Array Analysis

High throughput screening and statistical analysis performed to detect high-order chromosomal structures (i.e. a short list of CCS biomarker candidates for further analysis).

Episwitch® PCR Analysis

Translation and verification of selected marker candidates for further reduction and cross-validation of stratifying signatures, ready for validation.

Episwitch® NGS Analysis

High throughput sequencing and bioinformatic analysis to detect high-order chromosomal conformation signatures, ready for cross-validation by other modalities.


Episwitch® PCR Analysis

Validation of the Selected marker signatures on independent sample cohorts for use by OBD’s commercial partners.

Our Publications on Episwitch® Services

A blood-based epigenetic test for early detection of nasopharyngeal carcinoma (NPC).

Annual meeting of the American Society of Clinical Oncology; 2013 May 31- Jun 4; Chicago. Illinois, USA
J Clinical Oncology 31, 2013 (Supplement; Abstract 6063)


A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma.

Proceedings of the 104th Annual meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, District of Columbia, USA

Cancer Res 2013;73(8 Supplement):Abstract number LB-87


Breast cancer: development of early non-invasive diagnostics to reduce disease mortality and psychological outcomes.

Psychoonkologia, 2: 35–49, 2013